Galectin-3 is Associated with Heart Failure Incidence: A Meta-Analysis
Preprint
Abstract
Introduction Heart failure (HF) is a leading cause of death worldwide. The global prevalence of heart failure is projected to increase rapidly in the coming decades, and significant attention has turned to improving biomarker-based risk prediction of incident HF. The aim of this paper was to qualitatively and quantitatively evaluate the evidence associating levels of galectin-3 with risk of incident HF. Methods A review of PUBMED-indexed peer-reviewed literature was performed. Nine studies met inclusion criteria, and all nine had data eligible for conversion and pooling. A random-effects meta-analysis was performed using hazard ratios and 95% confidence intervals from a minimally adjusted model, a further adjusted model, and from subgroups within the further-adjusted model. Results The minimally-adjusted model provided a HR of 1.97 (95% CI 1.74-2.23) when comparing the top quartile of log-gal-3 to the bottom quartile. The further-adjusted model provided a HR of 1.32 (95% CI 1.21-1.44) for the same comparison. The positive, significant association was conserved during sensitivity analysis. Conclusion There is a significant positive association between levels of circulating galectin-3 and risk of incident heart failure. Given the complex mechanistic relationship between galectin-3 and cardiovascular pathophysiology, further investigation is recommended for possible implementation of galectin-3 into clinical risk prediction models.Keywords
All Related Versions
- Published version: Current Cardiology Reviews, 19 (3), 1.
This publication has 22 references indexed in Scilit:
- SWIFT-Review: a text-mining workbench for systematic reviewSystematic Reviews, 2016
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureEuropean Heart Journal, 2016
- Epidemiology and aetiology of heart failureNature Reviews Cardiology, 2016
- Predictive value of galectin-3 for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohortInternational Journal of Cardiology, 2015
- Clinical Risk Stratification Optimizes Value of Biomarkers to Predict New-Onset Heart Failure in a Community-Based CohortCirculation: Heart Failure, 2014
- Plasma Galectin 3 and Heart Failure Risk in the Physicians' Health StudyEuropean Journal of Heart Failure, 2013
- Galectin-3, a Marker of Cardiac Fibrosis, Predicts Incident Heart Failure in the CommunityJACC, 2012
- Methods for Summarizing the Risk Associations of Quantitative Variables in Epidemiologic Studies in a Consistent FormAmerican Journal of Epidemiology, 1996
- The cardiovascular health study: Design and rationaleAnnals of Epidemiology, 1991
- The Natural History of Congestive Heart Failure: The Framingham StudyNew England Journal of Medicine, 1971